In the area of personalized medicine for cancer, technologies that detect mutations and sequence DNA variants play an important role, because these alterations are related to therapeutic success, prognosis, and detection of residual cancer following surgical resection. The use of these technologies often presents challenges in the detection of minority alleles in clinical specimens, which can be masked by a high background of wild-type DNA. To date, there are different methodologies that address this issue and are capable of identifying known and/or unknown low-abundance mutations with high sensitivity (1 ), including the recently described COLD-PCR (coamplification at lower denaturation temperature PCR) (2) (3) (4) (5) . This novel form of PCR, developed by our group, enriches preferentially mutated DNA sequences over wild type by using a lower-temperature denaturation step during the cycling protocol [critical denaturation temperature (T c ) 6 ]. The T c is below the melting temperature (T m ) of the wild-type amplicon and permits the selective denaturation of the mutated sequences in every round of PCR, whereas wild-type sequences remain substantially double-stranded, thus amplifying less. Mutated DNA enrichment by COLD-PCR facilitates subsequent mutation detection. This method is applicable to both known and unknown mutation enrichment and can be integrated with downstream detection methodologies such as Sanger sequencing, high-resolution melting analysis (HRM), real-time PCR, and nextgeneration sequencing, among others (6 -9 ) . COLD-PCR has been used successfully by diverse groups for mutation detection in different targets such as v-Kiras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 7 (2, 7, 10 -15 ) , GNAS1 (GNAS complex locus) (16 ) ; IDH1 [isocitrate dehydrogenase 1 (NADPϩ)] (17 ); BRAF (v-raf murine sarcoma viral oncogene homolog B1) (18 ) ; EGFR (epidermal growth factor receptor) (11 ) ; fetal paternally inherited mutations of plasma (19, 20 ) ; and peach floral genes (21 ) .
The main challenge in the application of COLD-PCR is to establish precisely the correct T c , because a variation in critical temperature as small as Ϯ0.2-0.3°C could make it difficult to obtain satisfactory mutation enrichment. A consequence of this requirement is the inability to amplify diverse sequences simultaneously with a single thermocycling program because in general each amplicon has a different T c . As such, it would be highly desirable to enable enrichment of mutations in multiple sequences in existing PCR thermocyclers or in emerging, high-throughput PCR platforms (22, 23 ) before amplicon sequencing.
In this report we present a temperature-tolerant (TT) COLD-PCR approach (TT-COLD-PCR) that relaxes the stringency on the denaturation temperature and simultaneously amplifies different targets with diverse T c with a single cycling program. We combine TT-COLD-PCR with HRM (24, 25 ) , providing a rapid, simple, and sensitive screening method to confirm mutation enrichment before Sanger sequencing or other complimentary assays.
Materials and Methods

DNA AND TUMOR SAMPLES
Human male genomic DNA was obtained from Promega (cat. no. G1471) and used as a wild-type control. Genomic DNA from cell lines containing tumor protein p53 (TP53) mutations (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol58/ issue7) was purchased from American Type Culture Collection. Cells from the A549 lung carcinoma cell line with a defined KRAS mutation (p.G12S, c.34GϾA) were cultured in F12 medium supplemented with 10% fetal bovine serum at 37°C with 5% CO 2 . Genomic DNA from the A549 cells was extracted with a DNeasy Blood & Tissue Kit (Qiagen). DNA from clinical colorectal (n ϭ 4), glioblastoma (n ϭ 5), and lung (n ϭ 1) cancer specimens, previously reported to have mutations at different abundances detected by use of COLD-PCR (8, 26 ) and other independent methods, were used to further validate the technology (see online Supplemental Table 2 ). We also tested plasma-circulating DNA (obtained from a radiation therapy patient who gave informed consent, with institutional review board approval) that demonstrated a TP53 mutation. The plasma-circulating DNA was preamplified by ligationmediated PCR (LM-PCR) as previously described (27 ) , along with plasma-circulating DNA from a healthy donor (see online Supplemental Table 2 ).
PREAMPLIFICATION WITH CONVENTIONAL PCR FROM
GENOMIC DNA
We applied a conventional-PCR preamplification step from genomic DNA before testing TT approaches in a nested PCR format for the 3 forms of COLD-PCR, (fast-, full-, or ice-COLD-PCR). Primers for all forms of PCR were synthesized by Integrated DNA Technologies and are listed in online Supplemental Table 3 . PCR was performed in a 25-L final volume for all PCR reactions, with the Phusion TM high-fidelity DNA polymerase system (New England Biolabs).
Before performing nested TT-fast-and TT-ice-COLD-PCR, we conducted DNA preamplification by amplifying individual amplicons from genomic DNA to build enough template for subsequent COLD-PCR reactions. Before performing TT-full-COLD-PCR, we conducted genomic DNA preamplification of all TP53 exons simultaneously using a single-tube multiplex-PCR approach as reported previously (26 ) , with minor modifications. Reactions were carried out in a 15-L reaction volume consisting of 1ϫ Phusion high-fidelity buffer, 0.2 mmol/L (each) dNTPs, 0.1 mol/L (each) primers, and 0.6 U Phusion DNA polymerase. The resulting PCR product was then diluted 200-fold and used as a template for TT-full-COLD-PCR reactions, which were performed in separate tubes for each target amplicon. For comparison to COLD-PCR formats, a nested conventional PCR was always performed in parallel with TT-COLD-PCR.
CRITICAL DENATURATION TEMPERATURE WINDOW FOR TT-FULL-COLD-PCR
The T c is the temperature(s) at which the majority of the major alleles are inhibited while the minor alleles are selectively amplified. Although in previous COLD-PCR reports a discrete temperature for a given amplicon was required for robust enrichment, we present here an alternative that eases the requirement for strin-gency of the denaturation temperature while also offering satisfactory enrichment. The aim is to increase the denaturation temperature such that the mutant alleles are preferentially denatured and amplified before the wild-type alleles, even if they are present in amplicons with diverse T c . To achieve this, T m s of the wild-type target DNA sequences are experimentally determined with a conventional PCR in the presence of 1X LCGreen dye (Idaho Technologies), to define the initial T c . Alternatively, the amplicon T m can be predicted simply by use of bioinformatic tools (28 ) . The initial T c applied for TT-full-COLD-PCR is Ն1°C below the minimum T m (T mmin ) among all target amplicons tested, so that when the temperature increases gradually it first encounters the T c of the amplicon with the lowest T m . Thus, for TT-full-COLD-PCR we adopted: initial T c ϭ T mmin Ϫ 2°C. The TT-full-COLD-PCR protocol applied here consists of successive steps, with 7 cycles each step, where the T c is incremented at 0.5°C intervals between successive steps (Fig. 1 ).
TT-FULL-COLD-PCR REACTIONS
PCR thermocycling conditions are described in online Supplemental Tables 4 and 6 . Reaction conditions were the same for all cases except that for KRAS the concentration of primers was 0.075 mol/L each.
TT-FAST-COLD-PCR REACTIONS
PCR products from the genomic DNA preamplification were diluted 500 -1000-fold and used as a template for nested TT-fast-COLD-PCR reactions. We performed nested TT-fast-COLD-PCR on an Eppendorf Mastercycler machine (Eppendorf) using the "plate" block setting and "safe" temperature mode to ensure better well-to-well uniformity and to prevent overheating above the target temperatures (see online Supplemental Tables 4 and 5) . A single TT-fast-COLD-PCR program was used to amplify TP53 exons 6 -9. For TTfast-COLD-PCR we adopted: initial T c ϭ T mmin Ϫ 1.3°C (see online Supplemental Table 5 ). T m s for exon 7 and 8 amplicons were effectively reduced by adding 4% and 2% DMSO, so that amplicon T m fell within the TT-full-COLD-PCR for enrichment of diverse mutant sequences with a single PCR program. Each TT-full-COLD PCR step is repeated x times (x ϭ 7 herein), following which a new step at a T c incremented by 0.5°C is applied. In the present work, there are a total of 6 steps corresponding to a combined T c window of 2.5°C.
TT-fast-COLD-PCR temperature window applied in this investigation.
TT-ICE-COLD-PCR REACTIONS
Amplification via ice-COLD-PCR inhibits preferentially the amplification of one DNA strand in wild-type DNA (5 ), whereas the second strand remains uninhibited. In view of this effect, and to inhibit excessive amplification of the second strand, we performed the nested amplification reaction in an asymmetric-PCR mode, wherein the reverse primer was present at 5 times the concentration of the forward primer. Conventional PCR also was performed in asymmetric mode for comparative analysis. Reagent conditions for the conventional PCR were the same as reported for genomic amplification except for primer concentration, with 0.2 mol/L forward primer and 1.0 mol/L reverse primer, and 1 L of the diluted (1:5000-fold) amplicon from the genomic DNA preamplification. Reagent conditions for the ice-COLD-PCR reactions were the same as in the conventional assays but with the additional incorporation of a reference sequence (RS) at a 25 nmol/L concentration. The RS used was the same as previously described (5 ). For TT-ice-COLD-PCR, we examined a range of T c values below the T m of the amplicon tested before determining the optimal initial T c of 83.7°C that generated maximum enrichment for the temperature window applied (see online Supplemental Tables 7 and 8 ).
HRM AND SANGER SEQUENCING
We direcly analyzed TT-full-COLD-PCR and conventional amplicons using HRM on a Light Scanner HR96 system (Idaho Technologies) before sequencing. For Sanger sequencing, PCR products were digested by Exonuclease I/shrimp alkaline phosphatase and sequenced at Eton Bioscience. Owing to the short amplicon length, a 30-T tail was added to the 5Ј end of the sequencing primer as reported previously (29 ) . Chromatograms were then analyzed with BioEdit v7.1.3 (Ibis Biosciences). Mutant allele abundances relative to wild type were estimated from the peak height values of the Sanger sequencing chromatograms as previously reported (5 ). However, because Sanger sequencing is not quantitatively accurate, these estimations may not be precise.
Results
TT-FULL-COLD-PCR VS CONVENTIONAL PCR OR TRADITIONAL FULL-COLD-PCR
We evaluated the mutation enrichment obtained via TTfull-COLD-PCR compared to other forms of PCR. For this purpose, we amplified serial dilutions of DNA from mutation-containing cell lines for KRAS (c.34GϾA mutation, p.G12S) and TP53 exon 8 (c.841GϾC mutation, p. D281H) by conventional PCR; TT-full-COLD-PCR; and traditional, single-T c full-COLD-PCR before Sanger sequencing (Fig. 2) . In both cases, a 3% mutant content was not visible in the chromatogram of the conventional amplification, but was visible and enriched to approximately
Fig. 2. TT-full-COLD PCR evaluation for a 3% mutation abundance following dilution of the KRAS codon 12 G>A mutation (A) and TP53 exon 8 G>C mutation (B) into wild-type DNA.
TT-full-COLD PCR is compared to conventional PCR and to traditional full-COLD PCR performed at a single T c and followed by Sanger sequencing.
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19%-25% mutant content for KRAS and TP53 by traditional full-COLD-PCR and TT-full-COLD-PCR. The mutation enrichment, approximately 6 -8-fold, was evident for both types of COLD-PCR. The enrichment obtained from TT-full-COLD-PCR was somewhat less than that of single-T c COLD-PCR.
TT-FULL-COLD-PCR: A SINGLE THERMOCYCLING PROGRAM FOR DIVERSE TP53 AMPLICONS
Using the scheme illustrated in Fig. 1 , we applied universal thermocycling conditions spanning a window of denaturation temperatures from 85.2 to 87.7°C to simultaneously amplify and enrich for mutations in 4 different regions of the TP53 gene, exons 6 -9. The protocol applied was capable of enriching mutation abundances by approximately 4 -9-fold in all examined exons simultaneously, according to the results from Sanger sequencing (Fig. 3) . TT-full-COLD-PCR amplicons were also examined by HRM before sequencing and compared to HRM from the conventional PCR protocol. Fig. 4 shows an example of 2 of the amplicons tested via HRM; 148 bp of TP53 exon 6 (c.668CϾT, T m -reducing mutation) and 115 bp of TP53 exon 8 (c.841GϾC, T m -equivalent mutation) are presented. The exon 6 mutation is evident via HRM but cannot be confirmed by sequencing, whereas the exon 8 mutation cannot be confirmed by either HRM or sequencing following conventional PCR. In contrast, following TTfull-COLD-PCR the 3% mutation abundance is detectable via both HRM and sequencing. Additional HRM testing of DNA from cell lines with T m -reducing mutations in TP53 exon 8 (c.818GϾA) and exon 9 (c.925CϾT) are presented in online Supplemental Fig.  1 . On the basis of the magnitude of the HRM curve differentiation from wild-type DNA, we determined that the mutation detection sensitivity was notably higher in all TT-full-COLD-PCR amplicons compared to that obtained with conventional PCR amplicons. Finally, DNA from a cell line with a T m -increasing mutation (PFSK-1, c.823TϾG, p.C275G) for TP53 exon 8 was diluted into wild-type DNA to a final 4% or 2% mutation abundance and tested with TT-full-COLD-PCR or conventional amplification strategies. The data indicate that a mutation enrichment of approximately 7-14-fold was obtained, on the basis of the sequencing chromatograms (see online Supplemental Fig. 2 ).
TT-FULL-COLD-PCR HRM TESTING OF CLINICAL SAMPLES WITH LOW-LEVEL MUTATIONS
To further evaluate TT-full-COLD-PCR, we screened DNA from previously tested lung, colorectal, and glioblastoma tumor samples (26 ) containing high-, mid-, 
Sanger sequencing chromatograms depict results from conventional PCR (A) and TT-full-COLD-PCR amplification (B)
. The left and right columns in frame A correspond to the left and right columns in frame B.
and low-abundance mutations (see online Supplemental Table 2 ). Clinical samples were amplified by TT-full-COLD-PCR and conventional PCR, evaluated by HRM, and validated by Sanger sequencing ( Fig. 5 ; also see online Supplemental Fig. 3) . Fig. 5 depicts HRM profiles from a clinical sample, CT20, containing low-level mutations in both TP53 exons 8 and 9 following amplification with TT-full-COLD-PCR or alternatively via conventional PCR. Mutations are evident via HRM in both cases, but are visible only in the TT-full-COLD-PCR Sanger chromatograms, although the mutation in the exon 8 chromatogram is close to the limit of detection. Clinical samples containing mid-to highabundance mutations were also examined by HRM and sequencing. These mutations were detectable via both conventional and TT-full-COLD-PCR (not shown).
TT-FAST-COLD-PCR: TESTING OF SERIAL DILUTIONS AND
PLASMA-CIRCULATING DNA
Fast-COLD-PCR is useful for enriching the subset of mutations that decrease the T m of the amplicons G:CϾA:T and G:CϾT:A, which comprise the majority of somatic mutations in human cancer (7 ). Fast-COLD-PCR is a rapid protocol that generally results in higher enrichments than full-COLD-PCR. Thus, TT thermocycling was also adapted for fast-COLD-PCR format, for KRAS and TP53 exons 6 -9 mutations, in an Eppendorf thermocycler. Cycling conditions for KRAS spanned a temperature window from 82.7 to 85.3°C, and for TP53 a temperature window from 85.5 to 88.5°C (see online Supplemental Tables 4 and 5) . We tested for KRAS mutation enrichment by diluting cells from the A549 cell line (mutant in c.34GϾA, p.G12S) into wild-type DNA, amplifying by TT-fast-COLD-PCR or conventional PCR, and applying Sanger sequencing. Online Supplemental Fig. 4 demonstrates that after TT-fast-COLD-PCR, 3% and 10% mutation abundances increased to approximately 50% and 87%, respectively. Similarly, we applied a single TT-fast-COLD-PCR protocol for simultaneous enrichment of DNA with TP53 mutations in exon 6 (SNU-182, p.S215I), Following conventional PCR, the 3% exon 6 mutation is detected via HRM but not via sequencing; the 3% exon 8 mutation is detected via neither method. Following TT-full-COLD these mutations are detected with both HRM and sequencing, although in exon8 the enrichment is marginally discriminated from background. exon 7 (HCC2157, p.R248W), exon 8 (SW480, p.R273H), and exon 9 (SW480, p.P309S). Subsequent Sanger sequencing revealed mutation enrichment in all exons (see online Supplemental Fig. 5 ). To also demonstrate the application of TT-fast-COLD-PCR in the enrichment of low-level mutations in a clinical sample, we tested plasma-circulating DNA from a radiation therapy patient in whom a low-level mutation in TP53 exon 8 (c.847CϾT, p.R823C) had been identified via traditional fast-COLD-PCR. Plasma-circulating DNA isolated from a normal volunteer was tested in parallel. We preamplified the pair of plasma-circulating DNAs was via LM-PCR using the method we described (27 ) . To exclude the possibility of a polymerase-introduced error during the LM-PCR preamplification step, we also validated the mutation using fast-COLD-PCR directly from unamplified DNA isolated from plasma (not shown). Sanger sequencing of the conventional PCR product revealed no mutation (Fig. 6 ). In contrast, TT-fast-COLD-PCR product revealed an enrichment of the mutation to an abundance of approximately 77% in the patient circulating DNA sample (Fig. 6 ).
TT-ICE-COLD-PCR
We also adapted the TT-COLD-PCR to ice-COLD-PCR and compared the mutation enrichment obtained via conventional PCR, TT-ice-COLD-PCR, and ice-COLD-PCR at a single T c . We used DNA from a cell line with a T m -equivalent mutation (HCC1008, p.841GϾC, p.D281H) diluted into wild-type DNA to a final 3% mutation abundance. Following evaluation of a series of critical denaturation temperatures (see online Supplemental Table 8 ), it was shown that optimal mutation enrichment was observed when the initial T c was set approximately 5°C below the T m of the amplicon:RS90 duplex, which was subsequently increased by 0.5°C every 7 cycles, to a final T c of 2.5°C below the T m of the amplicon:RS90 duplex. The Sanger-sequencing results demonstrated that both TT-ice-COLD-PCR and ice-COLD-PCR at a single T c resulted in similar mutation enrichment, i.e., 3% mutation abundance was enriched to approximately 36% (see online Supplemental Fig. 6 ). (3, 4 ) is inexpensive and relatively easy to implement because the primary required modification The mutations in TP53 exons 8 and 9 were detectable with both methods following TT-full-COLD.
Discussion
COLD-PCR
relative to conventional PCR lies in the cycling protocol and the denaturation temperature. However, the requirement for strict reproducibility and precision (Ϯ0.3°C) in controlling the critical denaturation temperature can introduce significant variations between different laboratories, equipment, or experiments. Factors such as PCR buffer composition and lot may generate differences in amplicon T m and T c . Additionally, differences in temperature-ramping speed, or in actual temperature between wells in a single PCR machine, may also influence the mutation enrichment obtained during individual COLD-PCR reactions. To address such issues, in preliminary work Candau et al. (30 ) observed that gradual increase of denaturation temperature within a fine interval during fast-COLD-PCR ("touch-up" COLD-PCR) removes the well-to-well temperature inconsistencies that introduce variations to the mutation enrichment. This concept was expanded herein, to encompass a broader window of temperatures spanning 2.5-3°C, to achieve simultaneous mutation enrichment in diverse amplicons of substantially different T m by use of a single thermocycling program. TT conditions can be defined for all forms of COLD-PCR: full-, fast-, and ice-COLD-PCR. Using TT-full-COLD-PCR, we demonstrated simultaneous mutation enrichment in 4 TP53 exons whose T m spanned a 2.5°C temperature window with the use of a single thermocycling program. It can thus be reasonably expected that mutations in any other amplicon whose T m falls within the same temperature window would also be enriched, thereby enabling diverse PCR sequences to be enriched on a conventional PCR machine with a single thermocycling program in a high-throughput format. Furthermore, amplicons with a T m exceeding the applied temperature window can also be included via amplification in the presence of DMSO or other modifiers that lower the T m . It is possible to broaden the temperature window to encompass a wider range of T m or to apply a finer step between temperatures, i.e., 0.3°C instead of 0.5°C. This change may boost further the capabilities of TT-COLD-PCR; however, caution is required to avoid primer dimers resulting from increasing PCR cycles. Additional considerations include polymerase inactivation resulting from repeated heating, or reaching the maximum number of PCR cycles allowed by the thermocycler software. In practice, a balance among all these factors should be accom- Circulating tumor DNA isolated from plasma of a radiation therapy patient with a low-abundance mutation (c.847CϾT, R283C) was analyzed by use of conventional PCR, fast-COLD PCR at a single T c , and TT-fast-COLD-PCR. The mutational enrichment was compared to that obtained for a 10% mutation abundance and also with circulating DNA obtained from a healthy volunteer.
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plished to define optimal conditions for TT-COLD-PCR.
